| 1. |
- Pavlyuchenko, Valery N., et al.
(författare)
-
Hollow-particle latexes: Preparation and properties
- 2001
-
Ingår i: Journal of Polymer Science Part A. - : Wiley. - 0887-624X .- 1099-0518. ; 39:9, s. 1435-1449
-
Tidskriftsartikel (refereegranskat)abstract
- Hollow-particle latexes were prepared according to the following stages: (1) the preparation of the methyl methacrylate-methacrylic acid (MAA)-ethylene glycol dimethacrylate copolymer (I) latex, (2) the preparation of a shell (II) based on polystyrene or styrene-acrylonitrile-divinyl benzene copolymer polymerized onto copolymer (I) particles, and (3) the neutralization of the core (I) carboxyl groups with a base (NH4OH or NaOH) at temperatures close to the glass-transition temperature of the polymer (II). The neutralization resulted in the expansion of the particles and formed water-filled hollow particles. The microspheres had an overall diameter of 460-650 nm and a hollow diameter of 300-450 nm. Rheological studies and particle size measurements by transmission electron microscopy and dynamic light scattering of the copolymer (I) latex indicate that the maximum particle swelling occurred at an approximately equimolar MAA/base ratio. It was found that even without the neutralization of the MAA units, a small hollow formation in the latex particles occurred during stage 2 because one volume of the copolymer (I) retained about 8 volume parts of water. It was also discovered that the final hollow-particle geometry after neutralization depends on the shell copolymer thickness and type as well as on the conditions during stage 3, that is, the time, temperature, base type, and concentration. The opacifying ability of the synthesized hollow particles was investigated in latex coatings. The opacifying ability values were generally in agreement with the hollow-particle geometry. The only exception was related to the copolymer (I)/copolymer (II) ratio. The maximum hollow volume was obtained at this value equal to 1/8, whereas the highest opacifying ability was observed at 1/10.
|
|
| 2. |
- Grenander, A., et al.
(författare)
-
Antithrombin treatment in patients with traumatic brain injury : a pilot study
- 2001
-
Ingår i: J Neurosurg Anesthesiol. ; 13:1, s. 49-56
-
Tidskriftsartikel (refereegranskat)abstract
- This study will determine if early administration of antithrombin concentrate to patients with traumatic brain injury (TBI) can inhibit or significantly shorten the time of coagulopathy. The progress of brain injury monitored by computed tomographic scan (CT) was also assessed, as was the time needed for intensive care and outcome related to Glasgow outcome scale (GOS). Twenty-eight patients with isolated brain trauma verified with CT were included in either of two parallel groups. The Glasgow coma score (GCS) was mean 7.5, and median 7.0; signifying a moderate to severe traumatic brain injury but with a mortality of only 3.5%. The patients randomized to antithrombin treatment received a total of 100 U/kg BW during 24 hours. To measure hypercoagulability, soluble fibrin (SF), D-dimer (D-d), and thrombin-antithrombin complex (TAT) were assessed together with antithrombin (AT) and routine coagulation tests. Before treatment, SF, D-d, and TAT were markedly increased in both groups. Soluble fibrin and D-dimer (measured after treatment began) appeared to decrease faster in the AT group, and there was a statistically significant difference between the groups at 36 hours for SF and at 36 hours, 48 hours, and at Day 3 for D-d. Thrombin-antithrombin complex levels were very high in both groups but, surprisingly, showed no significant difference between the groups. The authors conclude that antithrombin concentrate administered to patients with severe TBI resulted in a marginal reduction of hypercoagulation. We could not detect any obvious influence by antithrombin on brain injury progress, on CT, or on outcome or time needed for intensive care.
|
|
| 3. |
|
|
| 4. |
- Korponay-Szabó, I R, et al.
(författare)
-
Elevation of IgG antibodies against tissue transglutaminase as a diagnostic tool for coeliac disease in selective IgA deficiency
- 2003
-
Ingår i: Gut. - : BMJ. - 0017-5749 .- 1468-3288. ; 52:11, s. 1567-1671
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: IgA serum autoantibodies against tissue transglutaminase (tTG) have an established diagnostic value in coeliac disease, and high efficacy tests are widely available for their detection. However, serological evaluation of IgA deficient subjects is still difficult.AIMS: To evaluate the diagnostic potential of IgG class anti-tTG autoantibodies measured quantitatively using an enzyme linked immunosorbent assay (ELISA) compared with immunofluorescent detection of coeliac autoantibodies.PATIENTS: We tested serum samples from 325 IgA deficient subjects, including 78 patients with coeliac disease, 73 disease controls, and 174 blood donors.METHODS: IgG antibodies against human recombinant tTG were measured with an ELISA. IgG antiendomysium antibodies (EMA) were assayed by indirect immunofluorescence on human jejunum and appendix sections.RESULTS: The IgG anti-tTG ELISA had a sensitivity of 98.7% and a specificity of 98.6%, and the correlation with IgG EMA titres was high (r(s)=0.91). One coeliac patient, initially negative in all autoantibody tests, displayed both IgG anti-tTG antibodies and IgG EMA during later gluten exposure. IgG anti-tTG antibodies and EMA titres showed significant decreases (p<0.001) in treated patients. The frequency of IgG anti-tTG autoantibody positivity was 9.8% among IgA deficient blood donors and 11 of the 12 positive subjects with known HLA-DQ haplotypes carried DQ2 or DQ8 alleles.CONCLUSIONS: IgG anti-tTG and IgG EMA autoantibody tests are highly efficient in detecting coeliac disease in IgA deficient patients. The high prevalence of coeliac antibodies among symptom free IgA deficient blood donors who also carry coeliac-type HLA-DQ genes indicates that all IgA deficient persons should be evaluated for coeliac disease.
|
|
| 5. |
- Naredi, S., et al.
(författare)
-
An outcome study of severe traumatic head injury using the "Lund therapy" with low-dose prostacyclin
- 2001
-
Ingår i: Acta Anaesthesiologica Scandinavica. - : Wiley-Blackwell. - 0001-5172 .- 1399-6576. ; 45:4, s. 402-406
-
Tidskriftsartikel (refereegranskat)abstract
- Background: There are two independent head injury outcome studies using the “Lund concept”, and both showed a mortality rate of about 10%, and a favourable outcome (Glasgow outcome scale, GOS 4 and 5) of about 70%. The Lund concept aims at controlling intracranial pressure, and improving microcirculation around contusions. Intracranial pressure is controlled by maintaining a normal colloid osmotic pressure and reducing the hydrostatic capillary pressure. Microcirculation is improved by ensuring strict normovolaemia and reducing sympathetic discharge. The endogenous substance prostacyclin with its antiaggregatory/antiadhesive effects may further improve microcirculation, which finds support from a microdialysis‐based clinical study and an experimental brain trauma study. The present clinical outcome study aims at evaluating whether the previously obtained good outcome with the Lund therapy can be reproduced, and whether the addition of prostacyclin has any adverse side‐effects.Methods: All 31 consecutive patients with severe head injury, Glasgow coma scale (GCS) ≤8, admitted to the University Hospital of Umeå during 1998 were included. The Lund therapy including prostacyclin infusion for the first three days at a dose of 0.5 ng kg−1 min−1. Outcome was evaluated according to the GOS >10 months after the injury.Results: One patient died, another suffered vegetative state and 7 severe disability. Of the 22 patients with favourable outcome, 19 showed good recovery and 3 moderate disability. No adverse side‐effects of prostacyclin were observed.Conclusion: The outcome results from previous studies using the Lund therapy were reproduced, and no adverse side‐effects of low‐dose prostacyclin were observed.
|
|
| 6. |
|
|
